A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations ... only head-to-head trial to date. It is reasonable to recommend ...

Combined airway valve therapy in severe emphysema improves lung function and walking distance for patients with heterogeneous disease, despite some risks.

The major findings of this study of exacerbations of COPD can be ... few days after treatment initiation rather than at 5 or 10 days; however, this has not been studied to date and was not ...

GlaxoSmithKline (GSK) has announced full results from the Salford Lung Study (SLS), a pioneering study of COPD treatment aimed ... rate of moderate or severe exacerbations by 8.4% compared to ...

COPD could open up a massive ... make them suitable for treatment with Nucala. Elevated eosinophil levels are associated with more severe COPD and a higher rate of exacerbations, the sudden ...

For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges. We ...

Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...